All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
Shaji Kumar, Mayo Clinic, Rochester, US, spoke with the Multiple Myeloma Hub about his recent paper “A simple additive staging system for newly diagnosed multiple myeloma” published in Blood Cancer Journal.
With reference to this paper, we asked, How might the MAYO Additive Staging System (MASS) score aid treatment decisions for newly diagnosed patients?
How might the MASS score aid treatment decisions for newly diagnosed patients?
Kumar begins his answer by describing the current situation regarding risk stratification in the field of multiple myeloma, including the role of the Revised International Staging System (R-ISS) and the importance of the inclusion of cytogenetic abnormalities, such chromosome 1q gain/amplification.
Kumar speaks on the creation of the MASS score using the ISS Stage III (serum β2-microglobulin ≥5.5 mg/L) and the other risk factors shown in Figure 1. Following on from this, the potential benefits of this scoring system are summarized.
Figure 1. MASS*
IGH, immunoglobulin heavy chain locus; ISS, International Staging System; LDH, lactate dehydrogenase; MASS, Mayo Additive Staging System; OS, overall survival; PFS, progression-free survival.
*Adapted from Abdallah, et al.1
How is the definition of high-risk MM evolving?
During the 3rd European Myeloma Network Meeting, the Multiple Myeloma hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How is the definition of high-risk multiple...
Novel risk score for predicting early relapse in patients with multiple myeloma
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure...
Incorporating PET imaging in a new risk stratification system for NDMM
Patients with newly diagnosed multiple myeloma (NDMM) are risk stratified according to the Revised International Staging System (R-ISS) designed by the International Myeloma...
Subscribe to get the best content related to multiple myeloma delivered to your inbox